Ryan Gentzler, MD· @ryangentzler · X·· 14 小时前评分70
正文 · 原文
Expert discussion of DeLLphi-305 by @StephenVLiu. Bringing tarlatamab to maintenance is major advance as second line tarlatamab is often “a promise we cannot keep.”
Many patients never receive 2nd line.
#ESMO26
43 浏览 · 0 赞 · 0 转发 · 1 回复
会议摘要
LBA3按 Presidential Symposium I 对上
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org帖内回复
- Ryan Gentzler, MD@ryangentzler
Another memorable quote from this talk: “these data deliver real hope where hope has been in short supply”
来源：Ryan Gentzler, MD · x.com